// App-Quantinova.ai

: Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Researchers

Presenter

  • Markus H. Moehler

Principal Investigators

  • Ken Kato

  • Hendrik-Tobias Arkenau

  • Do-Youn Oh

  • Josep Tabernero

  • Marcia Cruz-Correa

  • HongWei Wang

  • Hui Xu

  • Jiang Li

  • Silu Yang

  • Rui-hua Xu

Medical Centers

  • BeiGene, Ltd, Boston, MA

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Johannes-Gutenberg Universitat Mainz, Mainz, Germany

  • Sarah Cannon Research Institute, London, United Kingdom

  • University of Puerto Rico-Rio Piedras Campus, San Juan, PR

  • Department of Medical Melanoma and Sarcoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China

  • BeiGene, Ridgefield Park, NJ

  • BeiGene (Beijing) Co., Ltd., Beijing, China

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • National Cancer Center Hospital, Tokyo, Japan

Locations

  • Puerto Rico

  • United Kingdom

  • Republic of South Korea

  • United States

  • China

  • Japan

  • Germany

  • Spain

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • Programmed death-ligand 1

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Adrucil injection

  • Tislelizumab

  • Capecitabine

  • Oxaliplatin

  • Cisplatin

  • SP263

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03777657

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved